elapegademase

Also Known As:

Revcovi; elapegademase-lvlr

Networked: 3 relevant articles (3 outcomes, 2 trials/studies)

1.	Severe combined immunodeficiency due to adenosine deaminase deficiency 01/01/2023 - "REVCOVI is effective for the management of ADA-SCID." 01/01/2023 - "Safety and efficacy of elapegademase in patients with adenosine deaminase deficiency: A multicenter, open-label, single-arm, phase 3, and postmarketing clinical study." 01/01/2023 - "REVCOVI treatment in the ERT-naive group led to the resolution of many clinical and laboratory complications of ADA deficiency, whereas there were no new adverse effects among the transitioning patients. " 01/01/2023 - "Data on ERT, infectious and noninfectious complications, and metabolic and immune evaluations were collected from 17 patients with ADA-SCID treated for 6 months or more with REVCOVI. " 01/01/2023 - "To determine the real-life long-term benefits of REVCOVI in ADA-SCID. "
2.	Pain (Aches) 01/01/2023 - "One patient withdrew after 2 doses of an early elapegademase formulation due to injection-site pain caused by EDTA. "